|
Gene: MEGF11 |
Gene summary for MEGF11 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MEGF11 | Gene ID | 84465 |
Gene name | multiple EGF like domains 11 | |
Gene Alias | MEGF11 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | A6BM72 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84465 | MEGF11 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.50e-09 | 3.85e-01 | -0.0166 |
84465 | MEGF11 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 5.84e-12 | 4.74e-01 | -0.0132 |
84465 | MEGF11 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 5.64e-14 | 4.82e-01 | -0.013 |
84465 | MEGF11 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.77e-10 | 4.10e-01 | -0.0121 |
84465 | MEGF11 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 4.19e-03 | 5.13e-01 | -0.0961 |
84465 | MEGF11 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.40e-02 | 4.67e-01 | -0.0876 |
84465 | MEGF11 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 3.40e-04 | 5.53e-01 | -0.0822 |
84465 | MEGF11 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 1.31e-05 | 5.50e-01 | -0.0809 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Lung | AAH: Atypical adenomatous hyperplasia | |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00341098 | Lung | IAC | homotypic cell-cell adhesion | 19/2061 | 90/18723 | 3.82e-03 | 3.18e-02 | 19 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MEGF11 | SNV | Missense_Mutation | c.2685N>A | p.Met895Ile | p.M895I | A6BM72 | protein_coding | tolerated(0.55) | benign(0.005) | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD | |
MEGF11 | SNV | Missense_Mutation | c.142N>G | p.Gln48Glu | p.Q48E | A6BM72 | protein_coding | tolerated(0.14) | probably_damaging(0.965) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MEGF11 | SNV | Missense_Mutation | c.58C>G | p.Leu20Val | p.L20V | A6BM72 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
MEGF11 | SNV | Missense_Mutation | novel | c.1414C>A | p.Gln472Lys | p.Q472K | A6BM72 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AO-A12A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MEGF11 | SNV | Missense_Mutation | c.755N>A | p.Gly252Asp | p.G252D | A6BM72 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A1AS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
MEGF11 | SNV | Missense_Mutation | novel | c.1673C>T | p.Thr558Ile | p.T558I | A6BM72 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MEGF11 | SNV | Missense_Mutation | rs750174130 | c.2305A>C | p.Thr769Pro | p.T769P | A6BM72 | protein_coding | deleterious(0.04) | possibly_damaging(0.906) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEGF11 | SNV | Missense_Mutation | c.2628N>C | p.Gln876His | p.Q876H | A6BM72 | protein_coding | tolerated(0.06) | benign(0.025) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
MEGF11 | SNV | Missense_Mutation | rs750174130 | c.2305A>C | p.Thr769Pro | p.T769P | A6BM72 | protein_coding | deleterious(0.04) | possibly_damaging(0.906) | TCGA-D8-A1X7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
MEGF11 | insertion | Frame_Shift_Ins | novel | c.133_134insTGTCTCACTTTTCCATCCTCCTACCGGTACTTCCTAGGATT | p.Pro45LeufsTer256 | p.P45Lfs*256 | A6BM72 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
84465 | MEGF11 | NA | fluorouracil | FLUOROURACIL | 24444404 |
Page: 1 |